Cargando…
Gut microbiome and metabolic-associated fatty liver disease: Current status and potential applications
Metabolic-associated fatty liver disease (MAFLD) is one of the most common chronic liver diseases worldwide. In recent years, the occurrence rate of MAFLD has been on the rise, mainly due to lifestyle changes, high-calorie diets, and imbalanced dietary structures, thereby posing a threat to human he...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401411/ https://www.ncbi.nlm.nih.gov/pubmed/37547030 http://dx.doi.org/10.4254/wjh.v15.i7.867 |
_version_ | 1785084656553558016 |
---|---|
author | Guo, Gong-Jing Yao, Fei Lu, Wei-Peng Xu, Hao-Ming |
author_facet | Guo, Gong-Jing Yao, Fei Lu, Wei-Peng Xu, Hao-Ming |
author_sort | Guo, Gong-Jing |
collection | PubMed |
description | Metabolic-associated fatty liver disease (MAFLD) is one of the most common chronic liver diseases worldwide. In recent years, the occurrence rate of MAFLD has been on the rise, mainly due to lifestyle changes, high-calorie diets, and imbalanced dietary structures, thereby posing a threat to human health and creating heavy social and economic burdens. With the development of 16S sequencing and integrated multi-omics analysis, the role of the gut microbiota (GM) and its metabolites in MAFLD has been further recognized. The GM plays a role in digestion, energy metabolism, vitamin synthesis, the prevention of pathogenic bacteria colonisation, and immunoregulation. The gut-liver axis is one of the vital links between the GM and the liver. Toxic substances in the intestine can enter the liver through the portal vascular system when the intestinal barrier is severely damaged. The liver also influences the GM in various ways, such as bile acid circulation. The gut-liver axis is essential in maintaining the body’s normal physiological state and plays a role in the onset and prognosis of many diseases, including MAFLD. This article reviews the status of the GM and MAFLD and summarizes the GM characteristics in MAFLD. The relationship between the GM and MAFLD is discussed in terms of bile acid circulation, energy metabolism, micronutrients, and signalling pathways. Current MAFLD treatments targeting the GM are also listed. |
format | Online Article Text |
id | pubmed-10401411 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-104014112023-08-05 Gut microbiome and metabolic-associated fatty liver disease: Current status and potential applications Guo, Gong-Jing Yao, Fei Lu, Wei-Peng Xu, Hao-Ming World J Hepatol Review Metabolic-associated fatty liver disease (MAFLD) is one of the most common chronic liver diseases worldwide. In recent years, the occurrence rate of MAFLD has been on the rise, mainly due to lifestyle changes, high-calorie diets, and imbalanced dietary structures, thereby posing a threat to human health and creating heavy social and economic burdens. With the development of 16S sequencing and integrated multi-omics analysis, the role of the gut microbiota (GM) and its metabolites in MAFLD has been further recognized. The GM plays a role in digestion, energy metabolism, vitamin synthesis, the prevention of pathogenic bacteria colonisation, and immunoregulation. The gut-liver axis is one of the vital links between the GM and the liver. Toxic substances in the intestine can enter the liver through the portal vascular system when the intestinal barrier is severely damaged. The liver also influences the GM in various ways, such as bile acid circulation. The gut-liver axis is essential in maintaining the body’s normal physiological state and plays a role in the onset and prognosis of many diseases, including MAFLD. This article reviews the status of the GM and MAFLD and summarizes the GM characteristics in MAFLD. The relationship between the GM and MAFLD is discussed in terms of bile acid circulation, energy metabolism, micronutrients, and signalling pathways. Current MAFLD treatments targeting the GM are also listed. Baishideng Publishing Group Inc 2023-07-27 2023-07-27 /pmc/articles/PMC10401411/ /pubmed/37547030 http://dx.doi.org/10.4254/wjh.v15.i7.867 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Review Guo, Gong-Jing Yao, Fei Lu, Wei-Peng Xu, Hao-Ming Gut microbiome and metabolic-associated fatty liver disease: Current status and potential applications |
title | Gut microbiome and metabolic-associated fatty liver disease: Current status and potential applications |
title_full | Gut microbiome and metabolic-associated fatty liver disease: Current status and potential applications |
title_fullStr | Gut microbiome and metabolic-associated fatty liver disease: Current status and potential applications |
title_full_unstemmed | Gut microbiome and metabolic-associated fatty liver disease: Current status and potential applications |
title_short | Gut microbiome and metabolic-associated fatty liver disease: Current status and potential applications |
title_sort | gut microbiome and metabolic-associated fatty liver disease: current status and potential applications |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401411/ https://www.ncbi.nlm.nih.gov/pubmed/37547030 http://dx.doi.org/10.4254/wjh.v15.i7.867 |
work_keys_str_mv | AT guogongjing gutmicrobiomeandmetabolicassociatedfattyliverdiseasecurrentstatusandpotentialapplications AT yaofei gutmicrobiomeandmetabolicassociatedfattyliverdiseasecurrentstatusandpotentialapplications AT luweipeng gutmicrobiomeandmetabolicassociatedfattyliverdiseasecurrentstatusandpotentialapplications AT xuhaoming gutmicrobiomeandmetabolicassociatedfattyliverdiseasecurrentstatusandpotentialapplications |